JP2005502672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502672A5 JP2005502672A5 JP2003524529A JP2003524529A JP2005502672A5 JP 2005502672 A5 JP2005502672 A5 JP 2005502672A5 JP 2003524529 A JP2003524529 A JP 2003524529A JP 2003524529 A JP2003524529 A JP 2003524529A JP 2005502672 A5 JP2005502672 A5 JP 2005502672A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- angiogenic
- composition according
- coronary artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 210000004351 coronary vessel Anatomy 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical group N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims 2
- 102100035000 Thymosin beta-4 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108010079996 thymosin beta(4) Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000037891 myocardial injury Diseases 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31534701P | 2001-08-29 | 2001-08-29 | |
| PCT/US2002/027520 WO2003020215A2 (en) | 2001-08-29 | 2002-08-29 | Methods of treating mycocardial event related coditions with thymosin beta 4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123032A Division JP2009221211A (ja) | 2001-08-29 | 2009-05-21 | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502672A JP2005502672A (ja) | 2005-01-27 |
| JP2005502672A5 true JP2005502672A5 (enExample) | 2006-01-05 |
Family
ID=23223988
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524529A Pending JP2005502672A (ja) | 2001-08-29 | 2002-08-29 | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法 |
| JP2009123032A Ceased JP2009221211A (ja) | 2001-08-29 | 2009-05-21 | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123032A Ceased JP2009221211A (ja) | 2001-08-29 | 2009-05-21 | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9056087B2 (enExample) |
| EP (1) | EP1427432A4 (enExample) |
| JP (2) | JP2005502672A (enExample) |
| CN (2) | CN101549148A (enExample) |
| AU (1) | AU2002336408B2 (enExample) |
| CA (1) | CA2458883C (enExample) |
| MX (1) | MXPA04001942A (enExample) |
| WO (1) | WO2003020215A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2266595A3 (en) * | 2002-02-06 | 2011-07-06 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| WO2006076254A2 (en) * | 2005-01-11 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing respiratory microbial infection of respiratory tissue |
| US20080051348A1 (en) * | 2002-02-06 | 2008-02-28 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| CN1852727A (zh) * | 2003-03-31 | 2006-10-25 | 雷金纳克斯生物制药公司 | 递送胸腺素β4、类似物、同工型和其它衍生物的组合物和方法 |
| CA2532542A1 (en) * | 2003-07-18 | 2005-01-27 | Regenerx Biopharmaceuticals, Inc. | Treatment or prevention of damage due to radiation exposure |
| US20090053194A1 (en) * | 2003-12-22 | 2009-02-26 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| WO2005087805A1 (en) * | 2004-03-05 | 2005-09-22 | Regenerx Biopharmaceuticals, Inc. | Treating or preventing extracellular matrix build-up |
| JP2008510732A (ja) * | 2004-08-20 | 2008-04-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 心臓組織の損傷を処置、予防、阻害、または緩和する方法 |
| US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| CA2612522A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
| JP2009502938A (ja) * | 2005-07-26 | 2009-01-29 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | 鬱血性心不全が原因である組織の劣化、損傷、または破損を処置または予防する方法 |
| WO2007014254A2 (en) * | 2005-07-26 | 2007-02-01 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to hypertrophic muscle disease |
| CN100372572C (zh) * | 2005-09-29 | 2008-03-05 | 北京诺思兰德生物技术有限责任公司 | 携带人胸腺素β4基因的重组质粒 |
| US8399412B2 (en) * | 2006-10-06 | 2013-03-19 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions |
| HUP0600814A3 (en) * | 2006-10-27 | 2009-08-28 | Biostatin Gyogyszerkutato Fejl | Peptides for activation of angiogenesis, pharmaceutical compounds containing same and use of these compounds |
| MX2010010177A (es) * | 2008-03-17 | 2012-08-23 | Regenerx Biopharmaceuticals | Fragmentos de beta timosina mejorada. |
| KR101297037B1 (ko) * | 2010-03-26 | 2013-08-14 | 숙명여자대학교산학협력단 | 혈관신생촉진용 펩타이드 및 이의 용도 |
| BR112013000923A2 (pt) * | 2010-07-14 | 2016-05-17 | Adistem Ltd | método de tratamento de hiv ou aids |
| WO2012044783A2 (en) * | 2010-09-30 | 2012-04-05 | Regenerx Biopharmaceuticals, Inc. | Method of achieving a thymosin beta 4 concentration in a human patient |
| JP6889771B2 (ja) * | 2016-07-18 | 2021-06-18 | リジェンツリー リミテッド ライアビリティ カンパニー | ドライアイ症候群を治療する方法 |
| WO2021225960A2 (en) * | 2020-05-05 | 2021-11-11 | Regenerx Biopharmaceuticals, Inc. | Beta thymosin peptides for treating viral infections |
| CN111821424B (zh) * | 2020-07-21 | 2023-03-31 | 广东海洋大学深圳研究院 | 胸腺素及其衍生物的应用和治疗抑郁症的药物 |
| CN112023027B (zh) * | 2020-07-21 | 2023-03-14 | 广东海洋大学 | 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297276A (en) * | 1979-03-23 | 1981-10-27 | Hoffman-La Roche Inc. | Thymosin beta 3 and beta 4 |
| JPS61500431A (ja) | 1982-12-09 | 1986-03-13 | ビルトン,ジエラルド エル. | 傷治癒に有用な活性化され、安定化された酵素 |
| US4543340A (en) | 1983-04-07 | 1985-09-24 | George Washington University | Radioimmunoassay of thymosin β4 |
| JPH02124815A (ja) | 1987-10-29 | 1990-05-14 | Takeda Chem Ind Ltd | 血管形成促進剤 |
| US5654267A (en) | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
| JPH03178988A (ja) | 1989-09-14 | 1991-08-02 | Takeda Chem Ind Ltd | 生理活性物質tan―883、その製造法および用途 |
| CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| EP0725652A1 (en) | 1993-10-07 | 1996-08-14 | The George Washington University Medical Center | METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN $g(b) 4? |
| US5578570A (en) | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
| AU3733295A (en) | 1994-10-06 | 1996-05-02 | Alpha 1 Biomedicals, Inc. | Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i |
| US5663071A (en) | 1996-06-17 | 1997-09-02 | Children's Medical Center Corporation | Human thymosin β 15 gene, protein and uses thereof |
| US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| GB9806632D0 (en) | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| JP4301602B2 (ja) | 1998-09-28 | 2009-07-22 | 株式会社マルハニチロ水産 | 血管内皮細胞増殖促進剤 |
| PT1100529E (pt) | 1998-07-30 | 2005-10-31 | Us Gov Health & Human Serv | A timosina beta 4 promove a preparacao de feridas |
| US7560280B2 (en) * | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
-
2002
- 2002-08-29 AU AU2002336408A patent/AU2002336408B2/en not_active Ceased
- 2002-08-29 US US10/488,084 patent/US9056087B2/en not_active Expired - Lifetime
- 2002-08-29 CN CNA200910118323XA patent/CN101549148A/zh active Pending
- 2002-08-29 EP EP02773255A patent/EP1427432A4/en not_active Ceased
- 2002-08-29 WO PCT/US2002/027520 patent/WO2003020215A2/en not_active Ceased
- 2002-08-29 MX MXPA04001942A patent/MXPA04001942A/es active IP Right Grant
- 2002-08-29 JP JP2003524529A patent/JP2005502672A/ja active Pending
- 2002-08-29 CA CA2458883A patent/CA2458883C/en not_active Expired - Fee Related
- 2002-08-29 CN CNA028166884A patent/CN1547480A/zh active Pending
-
2009
- 2009-05-21 JP JP2009123032A patent/JP2009221211A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502672A5 (enExample) | ||
| CA2458883C (en) | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives | |
| RU2000109305A (ru) | ЗАЖИВЛЕНИЕ ПЕРЕЛОМОВ С ПОМОЩЬЮ АНАЛОГОВ ПЕПТИДА, ПОДОБНОГО ПАРАТИРЕОИДНОМУ ГОРМОНУ (РТНrР) | |
| DE69930872D1 (de) | Antikörper gegen verkürzten vegf-d und deren verwendungen | |
| JP2002509854A5 (enExample) | ||
| NO941186D0 (no) | Hormonanaloger med multiple CTP-forlengelser | |
| CA2223611A1 (en) | Appetite regulating compositions | |
| CA2727085A1 (en) | Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling | |
| ATE522563T1 (de) | Verzweigte polyalkylenglykole | |
| AU2002336408A1 (en) | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives | |
| DK0470117T3 (da) | Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner | |
| JP2005506293A5 (enExample) | ||
| EE05497B1 (et) | Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha | |
| CA2473996A1 (en) | Methods and compositions for the promotion of hair growth utilizing actin binding peptides | |
| US20060246057A1 (en) | Treatment or prevention of damage due to radiation exposure | |
| JP2004525988A5 (enExample) | ||
| ES2338633T3 (es) | Inhibicion o inversion del envejecimiento de la piel por medio de peptidos secuestradores de actina. | |
| JP2004527463A5 (enExample) | ||
| AU2004308378A1 (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent | |
| US20040067227A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
| US20240116990A1 (en) | Compositions and Methods of Treatment Using CRRL 191 | |
| KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 | |
| Rohde et al. | Structure of antigenic determinants in the N-terminal region of dermatosparactic sheep procollagen type I | |
| CA2558039A1 (en) | Treating or preventing extracellular matrix build-up | |
| ATE415415T1 (de) | Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist |